In the final post of our series, we’ll outline some of the key strategic questions that manufacturers must address.

In part three of our series, we explore the effects of the Globe and Guard CMMI MFN demonstration projects and their link to Medicare drug prices.

In part one of this series, we discuss the avenues that President Trump has looked into in order to engage MFN pricing with the Pharma Industry.

A few key insights from the recent AVBCC panel presentation on ex-U.S. drug access and pricing and how it could Impact MFN in the U.S.

It is time to move beyond DRGs and embrace a new framework to create more sustainable healthcare models.